Tags

Type your tag names separated by a space and hit enter

Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain.
Expert Opin Ther Targets. 2020 10; 24(10):1009-1028.EO

Abstract

INTRODUCTION

The sigma receptors are found abundantly in the central nervous system and are targets for the treatment of various diseases, including Alzheimer's (AD), Parkinson's (PD), Huntington's disease (HD), depression, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). However, for many of these diseases, other receptors and targets have been the focus of the most, such as acetylcholine esterase inhibitors in Alzheimer's and dopamine replacement in Parkinson's. The currently available drugs for these diseases have limited success resulting in the requirement of an alternative approach to their treatment.

AREAS COVERED

In this review, we discuss the potential role of the sigma receptors and their ligands as part of a multi receptor approach in the treatment of the diseases mentioned above. The literature reviewed was obtained through searches in databases, including PubMed, Web of Science, Google Scholar, and Scopus.

EXPERT OPINION

Given sigma receptor agonists provide neuroprotection along with other benefits such as potentiating the effects of other receptors, further development of multi-receptor targeting ligands, and or the development of multi-drug combinations to target multiple receptors may prove beneficial in the future treatment of degenerative diseases of the CNS, especially when coupled with better diagnostic techniques.

Authors+Show Affiliations

Age-related Inflammation and Degeneration Research Unit, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University , Bangkok, Thailand.Department of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University , Bangkok, Thailand.Department of Clinical Microscopy, Faculty of Allied Health Sciences, Chulalongkorn University , Bangkok, Thailand.Age-related Inflammation and Degeneration Research Unit, Department of Clinical Chemistry, Faculty of Allied Health Sciences, Chulalongkorn University , Bangkok, Thailand.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

32746649

Citation

Brimson, James Michael, et al. "Using Sigma-ligands as Part of a Multi-receptor Approach to Target Diseases of the Brain." Expert Opinion On Therapeutic Targets, vol. 24, no. 10, 2020, pp. 1009-1028.
Brimson JM, Brimson S, Chomchoei C, et al. Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opin Ther Targets. 2020;24(10):1009-1028.
Brimson, J. M., Brimson, S., Chomchoei, C., & Tencomnao, T. (2020). Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. Expert Opinion On Therapeutic Targets, 24(10), 1009-1028. https://doi.org/10.1080/14728222.2020.1805435
Brimson JM, et al. Using Sigma-ligands as Part of a Multi-receptor Approach to Target Diseases of the Brain. Expert Opin Ther Targets. 2020;24(10):1009-1028. PubMed PMID: 32746649.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Using sigma-ligands as part of a multi-receptor approach to target diseases of the brain. AU - Brimson,James Michael, AU - Brimson,Sirikalaya, AU - Chomchoei,Chanichon, AU - Tencomnao,Tewin, Y1 - 2020/08/31/ PY - 2020/8/5/pubmed PY - 2020/8/5/medline PY - 2020/8/5/entrez KW - Alzheimer’s disease KW - Parkinson’s disease KW - multi-targeting drugs KW - multiple Sclerosis KW - neurological disease KW - sigma receptors SP - 1009 EP - 1028 JF - Expert opinion on therapeutic targets JO - Expert Opin Ther Targets VL - 24 IS - 10 N2 - INTRODUCTION: The sigma receptors are found abundantly in the central nervous system and are targets for the treatment of various diseases, including Alzheimer's (AD), Parkinson's (PD), Huntington's disease (HD), depression, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). However, for many of these diseases, other receptors and targets have been the focus of the most, such as acetylcholine esterase inhibitors in Alzheimer's and dopamine replacement in Parkinson's. The currently available drugs for these diseases have limited success resulting in the requirement of an alternative approach to their treatment. AREAS COVERED: In this review, we discuss the potential role of the sigma receptors and their ligands as part of a multi receptor approach in the treatment of the diseases mentioned above. The literature reviewed was obtained through searches in databases, including PubMed, Web of Science, Google Scholar, and Scopus. EXPERT OPINION: Given sigma receptor agonists provide neuroprotection along with other benefits such as potentiating the effects of other receptors, further development of multi-receptor targeting ligands, and or the development of multi-drug combinations to target multiple receptors may prove beneficial in the future treatment of degenerative diseases of the CNS, especially when coupled with better diagnostic techniques. SN - 1744-7631 UR - https://www.unboundmedicine.com/medline/citation/32746649/Using_sigma_ligands_as_part_of_a_multi_receptor_approach_to_target_diseases_of_the_brain_ DB - PRIME DP - Unbound Medicine ER -